[PDF][PDF] 5-羟色胺及其受体与抑郁症
秦娟娟， 刘振华， 梁艳， 刘鹰， 张黎明， 李云峰 - 国际药学研究杂志, 2012 - jhak.com
… ,including monoamine reuptake inhibitors,monoamine oxidase inhibitors and monoamine
receptor ligand drugs. Although their therapeutic effect is definite,there are still serious defects,…
receptor ligand drugs. Although their therapeutic effect is definite,there are still serious defects,…
[PDF][PDF] 致幻剂的药理作用及其机制研究进展
孙毅， 苏瑞斌 - 中国药理学与毒理学杂志, 2021 - cjpt.magtechjournal.com
… In recent years, many clinical application studies have shown that psychedelics have the
therapeutic potential of analgesia, addiction, autoimmune diseases, depression, anxiety and …
therapeutic potential of analgesia, addiction, autoimmune diseases, depression, anxiety and …
二甲基色胺: 神经炎症和神经保护的生化“瑞士军刀”?
A Szabo, E Frecska - 中国神经再生研究(英文版), 2016 - sjzsyj.com.cn
… DMT as a potentially useful therapeutic tool in a broad range of chronic inflammatory and
autoimmune diseases, and pathological conditions connected to increased unfolded protein …
autoimmune diseases, and pathological conditions connected to increased unfolded protein …
阿戈美拉汀对癫痫及睡眠的影响.
毕锦玉， 孙美珍 - Practical Pharmacy & Clinical Remedies, 2023 - search.ebscohost.com
… 受体ꎬ 增加γ-氨基丁酸能细胞的放电速率ꎬ抑制单胺能 神经元ꎬ增加REM 睡眠ꎬ拮抗5-HT2C 受
… 抗抑郁药物ꎬ可通过拮抗5HT2C受体发挥抗抑郁作用[36] ꎮ 阻断5-HT2C受体 可以增加前额叶…
… 抗抑郁药物ꎬ可通过拮抗5HT2C受体发挥抗抑郁作用[36] ꎮ 阻断5-HT2C受体 可以增加前额叶…
[PDF][PDF] 以5-羟色胺2A受体为靶点的抗抑郁药研究进展*
徐祥清， 常山泉 - 医药导报, 2023 - yydbzz.com
… 5-… receptors antagonists enhanced the therapeutic effects of antidepressants such as
selective serotonin reuptake inhibitors (SSRIs) for treatment-resistant depression and reduced …
selective serotonin reuptake inhibitors (SSRIs) for treatment-resistant depression and reduced …
抗精神分裂症药物的新靶点和新机制
郭琳， 镇学初 - 神经药理学报, 2013 - actanp.hebeinu.edu.cn
… 5-HT2C 激动剂的抗精神分裂症的作用部分与其 调控DA 能神经元的功能有关.非选择性的5-HT2C
受体激动剂MK212 和选择性5-HT2C 受… 被5-HT2C 受体拮 抗剂SB-242,084 所拮抗[37]. 2.3 …
受体激动剂MK212 和选择性5-HT2C 受… 被5-HT2C 受体拮 抗剂SB-242,084 所拮抗[37]. 2.3 …
脂肪组织, 系统性炎症和神经退行性疾病
APA Boleti, PHO Cardoso, BEF Frihling… - 中国神经再生研究 …, 2023 - sjzsyj.com.cn
… like adrenalin, serotonin, dopamine, and GABA receptors (Adan et al., 2008). An example
is Lorcaserin, an anorectic drug active at 5-HT2C receptors in the hypothalamus., can act as a …
is Lorcaserin, an anorectic drug active at 5-HT2C receptors in the hypothalamus., can act as a …
治疗神经退行性疾病记忆障碍的新型药物: 阿戈美拉汀
Q Su, T Li, GW Liu, YL Zhang, JH Guo… - 中国神经再生研究 …, 2023 - sjzsyj.com.cn
… Compared with SSRIs and SSNRIs, AGO exerts an antidepressant effect by binding directly
to 5-HT2C receptors in postsynaptic membranes without affecting 5-HT concentrations in …
to 5-HT2C receptors in postsynaptic membranes without affecting 5-HT concentrations in …
[PDF][PDF] 抑郁症相关离子通道研究进展
吴梦瑶， 赵洪庆， 王宇红 - 中国临床药理学与治疗学, 2018 - manu41.magtech.com.cn
… Spatrigine could have therapeutic potential for major depression and bipolar depression
through antagonism ofthetwo-pore-domain K* channelTREK1[J]. Med Hypotheses,2008,70(3):…
through antagonism ofthetwo-pore-domain K* channelTREK1[J]. Med Hypotheses,2008,70(3):…
海马神经发生在脊髓损伤后抑郁中的潜在作用
Y Ma, Y Qiao, X Gao - 中国神经再生研究(英文版), 2024 - sjzsyj.com.cn
… possible mechanisms underlie this important spinal cord injury consequence. Finally, we
will outline the potential therapeutic … Third, we will point out potential therapeutic options that …
will outline the potential therapeutic … Third, we will point out potential therapeutic options that …